Area of research
Molecular Biology · Surgery
Research interest
Research interests include Methylation, Medicine, Bladder cancer, Prostate cancer, Oncology, and Cancer research.
Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer
Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer
Prognostic Value of Protocadherin10 (PCDH10) Methylation in Serum of Prostate Cancer Patients
Low expression of protocadherin7 (PCDH7) is a potential prognostic biomarker for primary non-muscle invasive bladder cancer
Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer
Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma
Aberrant Protocadherin17 (PCDH17) Methylation in Serum is a Potential Predictor for Recurrence of Early-Stage Prostate Cancer Patients After Radical Prostatectomy
Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer
Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer
Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma
Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer
Clinical significance of protocadherin-8 ( <i>PCDH8</i> ) promoter methylation in bladder cancer
The Clinical Significance of PCDH10 Promoter Methylation in Patients with Bladder Transitional Cell Carcinoma